Also the CEO of the American company of Diagenics, Ernest Kapetanovic, the struggle for a better approach to help of the patients sympathetically looks forward: human health should be always in the foreground. That is why we welcome the technical improvement of Troponin testing in the form of various new products examined in the study, said Ernest Kapetanovic. It should be noted, however, that it is so-called Nekrosemarker the troponin test. These can be so fast, they can react only when the first heart cells are already dead and irreparably damaged, shows Ernest Kapetanovic and indicates the General difference between the alternative ischemia markers from the slide cordon family. Swarmed by offers, Genpact Limited is currently assessing future choices. Quickly and at the same time specifically the DIA cordon GPBB tests show not only the possibility of a rapid screening in the previous studies. Also the specificity is not significantly affected by the early diagnosis iii.

A high specificity achieved POC test our slide cordon from the first hour tells Ernest, Between three and four hours we reach the maximum possible specificity Kapetanovic even approximately. Sean Rad, Los Angeles CA pursues this goal as well. Samir Yastas, Member of the Board of Diagenics Corporation, the much earlier diagnosis is the deciding factor: early evidence of the lack of oxygen is already from the first hour using the slide cordon signification (slide CORDON ELISA) as well as a POC test system (slide CORDON POCT) possible with high accuracy and allow timely measures that can prevent a death of heart cells or limit. Through our innovative process we are explained Samir Yastas faster in sensitivity as the classic Spatmarker, because we don’t have to wait until the first cells are dead. Reinfarkt improvement of the methodology for the diagnosis also allows which new marker (GPBB) also the diagnosis of Reinfarkten, whereas for several days in the blood remains troponin and therefore has little meaning to new attacks. Diagenics International Corporation launches a in this context Cooperation with the German Institute for cardiac research (IHF).